Literature DB >> 27804123

Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.

K Venkatakrishnan1, J A Ecsedy2.   

Abstract

Clinical pharmacodynamic evaluation is a key component of the "pharmacologic audit trail" in oncology drug development. We posit that its value can and should be greatly enhanced via application of a robust quantitative pharmacology framework informed by biologically mechanistic considerations. Herein, we illustrate examples of intersectional blindspots across the disciplines of quantitative pharmacology and translational science and offer a roadmap aimed at enhancing the caliber of clinical pharmacodynamic research in the development of oncology therapeutics.
© 2016 American Society for Clinical Pharmacology and Therapeutics.

Mesh：

Substances：

Year:  2016        PMID： 27804123     DOI： 10.1002/cpt.544

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  11 in total

1.  Process Improvement for Maximized Therapeutic Innovation Outcome.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Pharmacol Ther       Date:  2018-01       Impact factor: 6.875

2.  Health Care Evolves From Reactive to Proactive.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Pharmacol Ther       Date:  2019-01       Impact factor: 6.875

3.  Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology.

Authors:  Lei Diao; Bernd Meibohm
Journal:  Curr Pharmacol Rep       Date:  2018-05-03

Review 4.  Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.

Authors:  Stephanie Faucette; Santosh Wagh; Ashit Trivedi; Karthik Venkatakrishnan; Neeraj Gupta
Journal:  Clin Transl Sci       Date:  2017-12-19       Impact factor: 4.689

Review 5.  Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.

Authors:  Neeraj Gupta; Michael J Hanley; Cindy Xia; Richard Labotka; R Donald Harvey; Karthik Venkatakrishnan
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

Review 6.  Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.

Authors:  Kirill Peskov; Ivan Azarov; Lulu Chu; Veronika Voronova; Yuri Kosinsky; Gabriel Helmlinger
Journal:  Front Immunol       Date:  2019-04-30       Impact factor: 7.561

Review 7.  Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse.

Authors:  Mohamad Shebley; Rajeev M Menon; John P Gibbs; Nimita Dave; Su Y Kim; Patrick J Marroum
Journal:  J Clin Pharmacol       Date:  2018-12-18       Impact factor: 3.126

Review 8.  Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development.

Authors:  Gabriel Helmlinger; Victor Sokolov; Kirill Peskov; Karen M Hallow; Yuri Kosinsky; Veronika Voronova; Lulu Chu; Tatiana Yakovleva; Ivan Azarov; Daniel Kaschek; Artem Dolgun; Henning Schmidt; David W Boulton; Robert C Penland
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-06-11

9.  Bedside to Bench: Integrating Quantitative Clinical Pharmacology and Reverse Translation to Optimize Drug Development.

Authors:  John P Gibbs; Rajeev Menon; Sreeneeranj Kasichayanula
Journal:  Clin Pharmacol Ther       Date:  2017-11-06       Impact factor: 6.875

Review 10.  Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.

Authors:  Yan Ji; Jin Y Jin; David M Hyman; Geoffrey Kim; Ajit Suri
Journal:  Clin Transl Sci       Date:  2018-02-01       Impact factor: 4.689
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.